

Apollo Life Sciences Holdings Proprietary Limited
Balance Sheet As At March 31, 2025

		Amount in ZAR	
	Note No.	31-Mar-25	31-Mar-24
A ASSETS			
I Non-current assets			
Total non-current assets		-	-
II Current assets			
(a) Financial assets			
(i) Cash and cash equivalents	1	2,622	27,674
(b) Other Current assets	2	84,172	113,603
Total current assets		86,794	141,276
TOTAL ASSETS		86,794	141,276
B EQUITY AND LIABILITIES			
I Equity			
(a) Equity share capital	3	100	100
(b) Reserves and Surplus	4	(4,900)	(1,708)
Total Equity		(4,800)	(1,608)
II Liabilities			
1 Total non-current liabilities		-	-
2 Current liabilities			
(a) Financial liabilities			
(i) Trade payables	5	-	20,096
(b) Provisions	6	-	67,590
(c) Other current liabilities	7	89,158	55,199
(d) Current income tax liabilities	8	2,436	-
Total current liabilities		91,594	142,885
TOTAL EQUITY AND LIABILITIES		86,794	141,276

Apollo Life Sciences Holdings Proprietary Limited
Statement Of Profit And Loss For The Year Ended March 31, 2025

		Amount in ZAR		
	Particulars	Note No.	31-Mar-25	31-Mar-24
1	Revenue from operations	9	47,999	-
	Total Revenue		47,999	-
2	Expenses			
	(a) Finance costs	10	1,424	584
	(b) Other expenses	11	206,798	-
	Total expenses		208,223	584
3	Profit / (Loss) before exceptional items and taxes (1-2)		(160,224)	(584)
4	Exceptional Item		-	-
5	Profit / (Loss) before taxes		(160,224)	(584)
6	Tax Expense:			
	(a) Current tax		2,436	-
	Total tax expenses		2,436	-
7	Profit / (Loss) for the year after tax		(162,660)	(584)

Apollo Life Sciences Holdings Proprietary Limited
Notes forming part of financial statement

Note
No.

1	Cash and cash equivalents	Amount in ZAR	
	Particulars	31-Mar-25	31-Mar-24
	Balances with banks:		
	In current accounts	2,622	27,674
	Total	2,622	27,674
2	Other current assets	Amount in ZAR	
	Particulars	31-Mar-25	31-Mar-24
	Unsecured, considered good		
	Advances to other related entities	83,000	-
	- VAT receivable	1,172	13,602
	Total	84,172	-
3	Share capital	Amount in ZAR	
	Particulars	31-Mar-25	31-Mar-24
	Issued, subscribed and fully paid-up		
	Equity share capital	100	100
	Total	100	100
4	Reserves and surplus	Amount in ZAR	
	Particulars	31-Mar-25	31-Mar-24
	Surplus in statement of profit and loss		
	Opening balance	(1,708)	(1,124)
	Add: Profit / (Loss) for the year	(3,192)	(584)
	Closing balance	(4,900)	(1,708)
	Total	(4,900)	(1,708)
5	Trade payables	Amount in ZAR	
	Particulars	31-Mar-25	31-Mar-24
	Trade payable	-	20,096
	Total	-	20,096
6	Provisions	Amount in ZAR	
	Particulars	31-Mar-25	31-Mar-24
	Provision for expenses	-	67,590
	Total	-	67,590
7	Other current liabilities	Amount in ZAR	
	Particulars	31-Mar-25	31-Mar-24
	Advance received from customer	-	55,199
	Other short term provisions	89,159	
	Total	89,159	55,199
8	Current Income tax liability	Amount in ZAR	
	Particulars	31-Mar-25	31-Mar-24
	Provision for income tax (net of advance tax)	2,436	
	Total	2,436	-

Apollo Life Sciences Holdings Proprietary Limited
Notes forming part of financial statement

Note
No.

9	Revenue from operations	Amount in ZAR	
		31-Mar-25	31-Mar-24
	Particulars		
	Sale of Product	47,999	-
	Total	47,999	-

10	Finance cost	Amount in ZAR	
		31-Mar-25	31-Mar-24
	Particulars		
	Bank charges	1,424	584
	Total	1,424	584

11	Other expenses	Amount in ZAR	
		31-Mar-25	31-Mar-24
	Particulars		
	Rates & taxes	9,022	-
	Professional fees & Legal fees	197,777	-
	Total	206,798	-